| 中文摘要 |
子宮內膜癌的發生率正逐年上升，而傳統的化學治療及放射線治療對於晚期（第三/第四期）及復發後的病患，治療的預後無法顯著改善生存率。近年，免疫檢查點抑制劑療法（immune checkpoint inhibitor）的使用，已改變子宮內膜癌的治療，特別是對於那些DNA錯配修復功能缺陷（mismatch Repair Deficiency, MMRd）或高度微衛星不穩定（Microsatellite Instability-high, MSI-H）的患者。越來越多的證據支持將免疫療法與化療結合做為一線治療策略。最近，進行中的試驗，如RUBY trial（NCT03981796）的結果也支持這一點。對於第三/第四期有殘存腫瘤或復發轉移的內膜癌病患，以標準化學治療加上免疫療法，在有MMRd或MSI-H的內膜癌患者，可降低70%的疾病惡化進展的相對風險機率，對於DNA錯配修復功能無缺陷（mismatch Repair Proficiency,MMRp）或低度微衛星不穩定（microsatellite Instability-stable, MSI-S）的內膜癌患者，也可降低46%的疾病惡化進展的相對風險機率。因此，NCCN guideline已經將化學治療合併免疫治療列為第三/第四期有殘存腫瘤、復發性或轉移性子宮內膜癌第一線治療的選項。免疫治療正逐漸成為子宮內膜癌治療的新趨勢，並有望帶來顯著的變革。 |
| 英文摘要 |
The incidence of endometrial cancer is on the rise, and traditional therapies like chemotherapy and radiotherapy have shown limited efficacy in advanced (stage III/IV) and recurrent cases. Recently, the introduction of immune checkpoint inhibitors has significantly impacted the treatment landscape for endometrial cancer, particularly in patients with DNA mismatch repair deficiency (MMRd) or high microsatellite instability (MSI-H). Increasing evidence supports the integration of immunotherapy with chemotherapy as a first-line treatment approach. For example, ongoing trials, including the RUBY trial (NCT03981796), reinforce this strategy. In patients with MMRd or MSI-H, the combination of standard chemotherapy with immunotherapy can reduce the relative risk of disease progression by 70%. Even among patients without mismatch repair deficiency (MMRp) or those with microsatellite stable disease (MSI-S), the risk reduction is around 46%. Due to these findings, the NCCN (National Comprehensive Cancer Network) guidelines have now included the combination of chemotherapy and immunotherapy as a first-line treatment option for patients with stage III/IV endometrial cancer, particularly those with residual tumors, recurrent disease, or metastasis. Immunotherapy is emerging as a novel therapeutic option for endometrial cancer, and substantial improvements are anticipated. |
本站僅提供期刊文獻檢索。
